Facebook
X
LinkedIn
ForwardUW-NIL: Pharmacological Implications of Hereditary Cancer Disorders and Management - August 17, 2026
Overview
This joint presentation by the genetics and pharmacy teams will provide an overview of hereditary cancer syndromes, including BRCA1, BRCA2, and Lynch syndrome, and review how genetic test results can help guide cancer treatment decisions. Furthermore, the session will introduce pharmacogenomic testing and discuss how inherited genetic differences may influence medication selection and response in clinical practice.
Elements of Competence
This activity has been designed to change learner competence and focuses on the following competencies:
American Board of Medical Specialties
- Medical Knowledge
- Employ Evidence-based practices
Interprofessional Education Collaborative Competencies
- Roles and Responsibilities
Intended Audience
This activity is designed to meet the educational needs of nurses and pharmacists.
Learning Objectives
As a result of this activity, participants, as members of the healthcare team, will be able to:
- Identify key features of Lynch syndrome and hereditary breast and ovarian cancer, including associated cancer risks and clinical management strategies.
- Outline clinical indicators of hereditary cancer risk and the appropriate management of genetic testing.
- Explain the impact of pharmacogenomics on medication selection, optimal dosing, and toxicity management.
Course summary
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
Agenda
In-Service Agenda: Hereditary Cancer & Pharmacogenomics
Date: August 17, 2026 | Time: 4:00 PM – 5:00 PM (1 Hour)
| Time | Topic | Presenter(s) |
| 4:00 PM - 4:05 PM | Introduction, Disclosures & Session Objectives | |
| 4:05 PM - 4:15 PM | Module 1: Hereditary Breast and Ovarian Cancer (HBOC) | Miranda Cox Katie Loehr |
| 4:15 PM - 4:25 PM | Module 2: Lynch Syndrome | Miranda Cox Katie Loehr |
| 4:25 PM - 4:45 PM | Module 3: Pharmacogenomics and Medications • Impact on Selection, Dosing, and Toxicity | Katie Loehr |
| 4:45 PM - 5:00 PM | Summary & Key Takeaways | Miranda Cox & Katie Loehr |
UW Health Carbone Cancer Center, Rockford, IL
Planners & Presenters
Kate Rollins, BSN, RN
Miranda Cox, MS
Katie Loehr, PharmD
Policy on Disclosure
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate, and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence the content of this accredited continuing education (CE). In addition, speakers, presenters, and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentations. For this accredited continuing education activity, all relevant financial relationships have been mitigated, and detailed disclosures are listed below.
Name | Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved uses of drugs/devices in your presentation? |
| Kate Rollins | Planner/Chair | No relevant relationships with ineligible companies to disclose | No |
| Miranda Cox | Planner/Speaker | No relevant relationships with ineligible companies to disclose | No |
| Katie Loehr | Planner/Speaker | No relevant relationships with ineligible companies to disclose | No |
*Ineligible companies are those whose primary business is producing, marketing, selling, re‐selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
Accreditation and Credit Designation Statements
| Accreditation Logo | Accreditation Statement |
|---|---|
 | In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. |
Accreditation Council for Pharmacy Education (ACPE) The University of Wisconsin–Madison ICEP designates this knowledge-based activity for a maximum of 1.0 hours or 0.1 CEUs of CPE credit. Credit can be earned by successfully completing the activity and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. 2026 Universal Activity Number (UAN): JA0000358-0000-26-060-L01-P By completing the required components of this activity, you give UW-Madison ICEP permission to share completion data with the ACCME, certifying boards, and/or NABP. | |
American Nurses Credentialing Center (ANCC) The University of Wisconsin–Madison ICEP designates this live in-person activity for a maximum of 1.00 ANCC contact hours. | |
Continuing Education Units (CEUs) The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.100 CEUs or 1.00 hours. |
Available Credit
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
Accessibility
We value inclusion and access for all participants and are pleased to provide reasonable accommodation for this event. Please contact [email protected] as soon as you can make a reasonable accommodation request.